🟢 Iovance Biotherapeutics is trading 10.16% up today after Barclays raised its price target to $15

Iovance Biotherapeutics is trading 10.16% up at $10.87 after Barclays maintained its Overweight rating and raised its price target from $13 to $15 on September 17, 2026.

• The revised target represents roughly 52% upside from the September 16 close, according to market coverage.
• Biotechnology sector ETF XBI is up 2.55%, adding sector support amid a broader risk-on market rally.